

Guide to Using Pandemic H1N1 Influenza Vaccines

November 18, 2009

	Adjuvanted	Unadjuvanted	
Trade name	Arepanrix™	Influenza A (H1N1) 2009 Pandemic Monovalent Vaccine (Without Adjuvant)	Panvax®
Description	Adjuvanted H1N1 pandemic influenza vaccine	Unadjuvanted H1N1 pandemic influenza vaccine from Canada	Unadjuvanted H1H1 pandemic influenza vaccine from Australian
Indicated for	<ul style="list-style-type: none"> • Everyone 6 months of age or older • Can be used in pregnant women 	<ul style="list-style-type: none"> • Pregnant women • Healthy people 10 to 64 years of age 	<ul style="list-style-type: none"> • Pregnant women* • Healthy people 10 to 64 years of age
Use in pregnancy	Greater than 20 weeks gestation OR less than 20 weeks gestation & chronic health condition - consider Arepanrix™	Recommended at all stages of pregnancy	Recommended at all stages of pregnancy
Use in people with chronic medical conditions	Recommended H1N1 product	Not preferred	Not preferred
Use in children 6 months to < 10 years	Recommended	Not recommended	Not recommended
Use in people 65 years of age and older	Recommended	Not recommended	Not recommended
First dose	<ul style="list-style-type: none"> • 0.25 ml for 6 months to less than 10 years • 0.5 ml for 10 years and older 	0.5 ml for 10 years and older	0.5 ml
Second dose	<ul style="list-style-type: none"> • 0.25 ml for 6 months to less than 3 years • 0.25 ml for 3 years to less than 10 years with chronic medical conditions At least 21 days from first dose	Not applicable	Not applicable
Time to use before discarding	Use within 24 hours of mixing adjuvant and antigen (Stable for 24 hours at room temperature AFTER reconstitution)	Use within 28 days of first puncturing the vial (Store at 2-8°C in between vaccinations)	Use within 28 days of first puncturing the vial (Store at 2-8°C in between vaccinations)

* Panvax® was initially obtained for the purpose of immunizing pregnant women. However, it can also be used to immunize healthy people from 10 to 64 years of age.